• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    BioHarvest Launches Informed Sport-Certified VINIA DailyChews 2X Formula for Athletes and People with Active Lifestyles

    6/4/25 7:00:00 AM ET
    $BHST
    Get the next $BHST alert in real time by email

    Rehovot, Israel--(Newsfile Corp. - June 4, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced the launch of VINIA® DailyChews 2X Formula, a first-of-its-kind chew designed to increase nitric oxide production and arterial dilation, and to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles. VINIA® DailyChews 2X Formula are now available for purchase in a 30-count pack on VINIA.com.

    Formulated with a double dose of BioHarvest's proprietary red grape cell composition, VINIA® DailyChews 2X Formula are officially Informed Sport-certified, underscoring the Company's commitment to cleaner, safer, and effective performance nutrition. The globally recognized certification ensures every batch is tested for banned substances, making it a trusted choice for professional athletes, military personnel, and fitness enthusiasts alike.

    Each individually packaged VINIA® DailyChews 2X Formula contains 800mg of VINIA® and 12 mg of Piceid resveratrol, which has been clinically shown to increase arterial dilation. This arterial dilation improves blood flow, delivering more oxygen and nutrients to the body's muscles, tissues, and cells, improving physical energy and mental alertness.*

    "Our customers lead dynamic, high-performance lives, and they deserve a product that meets the highest standards for efficacy, safety and ease of use," said Ilan Sobel, CEO of BioHarvest. "The launch of VINIA® DailyChews 2x Formula - with Informed Sport certification - marks a major milestone as we expand into the athlete and fitness enthusiast segment of the multi-billion-dollar nutraceuticals market and address a younger consumer base. In addition, our new international ecommerce platform enables global orders, so that customers in countries which allow importation of supplements, such as the UK and Australia, can now have VINIA® products delivered directly to their doorstep with local tax and import fee calculations handled automatically on the backend.

    "This launch complements our growing VINIA® Inside portfolio, which includes the core capsule business and hot beverage line of teas and coffees, reflecting our broader strategy to meet increasing global demand for plant-based, science-backed solutions," concluded Sobel.

    *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

    About Informed Sport

    Informed Sport is the world's leading testing and certification program for brands producing sports and nutritional supplements. Designed for elite sport, it protects athletes from inadvertent doping caused by supplements contaminated with banned substances. As such, it is recognised by sporting and governing bodies, anti-doping bodies and nutrition industry organisations, and the armed and special forces. https://sport.wetestyoutrust.com/

    About BioHarvest Sciences Inc.

    BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

    Forward-Looking Statements

    Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

    BioHarvest Corporate Contact:
    Dave Ryan, VP Investor Relations
    +1 (604) 622-1186
    [email protected]

    Investor Relations Contact:
    Lucas A. Zimmerman
    Managing Director
    MZ Group - MZ North America
    +1 (949) 259-4987
    [email protected]

    Corporate Logo

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254440

    Get the next $BHST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BHST

    DatePrice TargetRatingAnalyst
    5/5/2025$15.00Buy
    Craig Hallum
    12/18/2024$12.00Buy
    Maxim Group
    More analyst ratings

    $BHST
    Leadership Updates

    Live Leadership Updates

    See more
    • BioHarvest Announces Appointment of Sharon Malka to Board of Directors

      Veteran Technology Leader Brings 25+ Years of Financial and Capital Markets Experience to the BoardVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 22, 2025) - BioHarvest Sciences Inc., (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest. The appointment is effective immediately."We are very pleased to announce the addition of Mr. Malka to the BioHarvest Board of Directors," said Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division

      1/22/25 8:30:00 AM ET
      $BHST

    $BHST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on BioHarvest Sciences with a new price target

      Craig Hallum initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $15.00

      5/5/25 8:30:45 AM ET
      $BHST
    • Maxim Group initiated coverage on BioHarvest Sciences with a new price target

      Maxim Group initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $12.00

      12/18/24 8:10:03 AM ET
      $BHST

    $BHST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioHarvest Launches Informed Sport-Certified VINIA DailyChews 2X Formula for Athletes and People with Active Lifestyles

      Rehovot, Israel--(Newsfile Corp. - June 4, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced the launch of VINIA® DailyChews 2X Formula, a first-of-its-kind chew designed to increase nitric oxide production and arterial dilation, and to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles. VINIA® DailyChews 2X Formula are now available for purchase in a 30-count pack on VINIA.com.Formulated with a double dose of BioHarvest's proprietary red grape cell composition, VINIA® DailyChews 2X Formula are officially Informed

      6/4/25 7:00:00 AM ET
      $BHST
    • BioHarvest Secures New CDMO Contract to Develop Plant-based Fragrance Compound

      First CDMO Project to Utilize In-house AI Tools for Discovery of Plant Cell Targets for the Botanical Synthesis ProcessRehovot, Israel--(Newsfile Corp. - May 21, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's Botanical Synthesis CDMO Services division has secured a new contract to develop a plant-based fragrance compound derived from a plant that is under significant threat due to over harvesting and habitat loss. This agreement is with a new commercial partner targeting the multi-billion-dollar fragrance and scents market.Ahead of the sig

      5/21/25 8:30:00 AM ET
      $BHST
    • Diamond Equity Research Releases Update Note on BioHarvest Sciences Inc. (NASDAQ: BHST)

      New York, May 21, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on BioHarvest Sciences Inc. (NASDAQ:BHST). The update note includes detailed information on the BioHarvest Sciences' financial results, operational updates, business model, management commentary, valuation, and risks. The update note is available below. BioHarvest Sciences May 2025 Update Note  Highlights from the note include:       Q1 Results Surpass Expectations on VINIA Strength and Operating Efficiencies:  BioHarvest Sciences reported robust financial performance for the first quarter of 2025, with rev

      5/21/25 8:00:00 AM ET
      $BHST

    $BHST
    SEC Filings

    See more
    • SEC Form 6-K filed by BioHarvest Sciences Inc.

      6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

      6/4/25 2:33:57 PM ET
      $BHST
    • SEC Form 6-K filed by BioHarvest Sciences Inc.

      6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

      5/21/25 2:48:39 PM ET
      $BHST
    • SEC Form 6-K filed by BioHarvest Sciences Inc.

      6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

      5/15/25 4:49:56 PM ET
      $BHST

    $BHST
    Financials

    Live finance-specific insights

    See more
    • BioHarvest Sciences Reports First Quarter 2025 Financial Results

      First Quarter Revenues Grew 47% to $7.9 Million, Exceeding Management GuidanceRehovot, Israel--(Newsfile Corp. - May 15, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the first quarter ended March 31, 2025.First Quarter & Subsequent 2025 Operational HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the first quarter of 2025 increased 47% year-over-year to $7.9 million, exceeding management guidance, with gross margins expanding by 227 basis points to 58.

      5/15/25 4:05:00 PM ET
      $BHST
    • BioHarvest Sciences to Host First Quarter 2025 Earnings Call on May 15 at 4:30 p.m. Eastern Time

      Rehovot, Israel--(Newsfile Corp. - May 1, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 15, 2025.Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on Thursday, May 15, 2025 to discuss the Company's first quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the following information:First Quarter

      5/1/25 8:30:00 AM ET
      $BHST
    • BioHarvest Sciences Reports Fourth Quarter and Full Year 2024 Financial Results

      Fourth Quarter Revenues Grew 62% to $7.3 Million, Exceeding Prior Management Guidance, with Full Year Revenues Increasing 99% Year-Over-Year to $25.2 MillionCDMO Division Secures Anchor Partnership with Tate & Lyle to Develop Next Generation of Plant-Based SweetenersRehovot, Israel--(Newsfile Corp. - March 31, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2024.Fourth Quarter 2024 & Subsequent Operational HighlightsAll figures stated in this news release are in U.S.

      3/31/25 4:05:00 PM ET
      $BHST